Payment overview · 2025
General Payments
$679.51
25 reported records · 9 companies
Healthcare provider profile · identity verified
Jiman Jung, NP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · DIAMOND BAR, CA · NPI 1093082885
Verified facts
What the public records show
CMS Open Payments records show Jiman Jung, NP received $679.51 in general payments during 2025 across 25 reported records.
Lilly USA, LLC accounted for 34.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Farxiga, Jardiance, Kerendia, Linzess, Mounjaro, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Linzess by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Zenpep by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 248 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Kerendia by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 151 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $234.06 | 34.5% | 6 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $144.50 | 21.3% | 6 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $83.21 | 12.2% | 4 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $56.77 | 8.3% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $51.50 | 7.6% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $46.90 | 6.9% | 2 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $23.99 | 3.5% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $20.38 | 3.0% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $18.20 | 2.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $679.51 | 25 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $196.11 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $144.50 | 6 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $83.21 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $76.46 | 3 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $56.77 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $51.50 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $46.90 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $37.95 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $24.13 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $23.99 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $22.13 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $19.96 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $18.20 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 79 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 248 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 151 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 48 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 51 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
79 | 24 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
51 | 11 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
22 | 16 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
248 | 48 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
151 | 30 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 940 | 235 |
| Amlodipine Besylate | Amlodipine Besylate | 582 | 141 |
| Losartan Potassium | Losartan Potassium | 511 | 127 |
| Metformin Hcl | Metformin Hcl | 329 | 83 |
| Tamsulosin Hcl | Tamsulosin Hcl | 280 | 78 |
| Vascepa | Icosapent Ethyl | 256 | 51 |
| Farxiga | Dapagliflozin Propanediol | 248 | 48 |
| Jardiance | Empagliflozin | 151 | 30 |
| Gabapentin | Gabapentin | 148 | 43 |
| Metformin Hcl Er | Metformin Hcl | 136 | 34 |
| Omeprazole | Omeprazole | 130 | 49 |
| Alendronate Sodium | Alendronate Sodium | 128 | 47 |
| Finasteride | Finasteride | 123 | 36 |
| Pantoprazole Sodium | Pantoprazole Sodium | 122 | 34 |
| Levothyroxine Sodium | Levothyroxine Sodium | 121 | 31 |
| Montelukast Sodium | Montelukast Sodium | 106 | 39 |
| Donepezil Hcl | Donepezil Hcl | 102 | 23 |
| Celecoxib | Celecoxib | 101 | 44 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 101 | 62 |
| Metoprolol Succinate | Metoprolol Succinate | 96 | 27 |
| Sertraline Hcl | Sertraline Hcl | 95 | 26 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 93 | 36 |
| Pioglitazone Hcl | Pioglitazone Hcl | 92 | 22 |
| Simvastatin | Simvastatin | 90 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 88 | 39 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 86 | 23 |
| Januvia | Sitagliptin Phosphate | 84 | 13 |
| Azithromycin | Azithromycin | 81 | 70 |
| Alcohol Swabs | Alcohol Antiseptic Pads | 80 | 23 |
| Creon | Lipase/Protease/Amylase | 79 | 24 |
| Lisinopril | Lisinopril | 79 | 18 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 78 | 42 |
| Fenofibrate | Fenofibrate,micronized | 71 | 20 |
| Icosapent Ethyl | Icosapent Ethyl | 68 | 32 |
| Naproxen | Naproxen | 66 | 46 |
| Clopidogrel | Clopidogrel Bisulfate | 63 | 14 |
| Meloxicam | Meloxicam | 63 | 30 |
| Sildenafil Citrate | Sildenafil Citrate | 58 | 14 |
| Trazodone Hcl | Trazodone Hcl | 57 | 17 |
| Mirtazapine | Mirtazapine | 55 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 51 | 11 |
| Myrbetriq | Mirabegron | 50 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 49 | 18 |
| Atenolol | Atenolol | 49 | suppressed |
| Memantine Hcl | Memantine Hcl | 48 | suppressed |
| Mounjaro | Tirzepatide | 48 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 47 | 16 |
| Alcohol Pads | Alcohol Antiseptic Pads | 46 | 13 |
| Famotidine | Famotidine | 45 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 44 | suppressed |
| Ibuprofen | Ibuprofen | 43 | 32 |
| Mupirocin | Mupirocin | 43 | 30 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 42 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 41 | 13 |
| Tradjenta | Linagliptin | 41 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 39 | 11 |
| Fluocinonide | Fluocinonide | 38 | suppressed |
| Glipizide Er | Glipizide | 38 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 38 | suppressed |
| Allopurinol | Allopurinol | 37 | suppressed |
| Carvedilol | Carvedilol | 36 | suppressed |
| Eliquis | Apixaban | 34 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 34 | 13 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 34 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 33 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 33 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Ciclopirox | Ciclopirox | 32 | 12 |
| Evenity (2 Syringes) | Romosozumab-Aqqg | 32 | suppressed |
| Glipizide | Glipizide | 32 | suppressed |
| Hydrocortisone | Hydrocortisone | 32 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 32 | suppressed |
| Glimepiride | Glimepiride | 31 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 30 | suppressed |
| Cephalexin | Cephalexin | 29 | 23 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 29 | 26 |
| Diclofenac Sodium | Diclofenac Sodium | 29 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 29 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 28 | suppressed |
| Rybelsus | Semaglutide | 28 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 26 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 26 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 25 | suppressed |
| Amoxicillin | Amoxicillin | 23 | 20 |
| Doxazosin Mesylate | Doxazosin Mesylate | 23 | suppressed |
| Digoxin | Digoxin | 22 | suppressed |
| Pregabalin | Pregabalin | 22 | suppressed |
| Prolia | Denosumab | 22 | 16 |
| Xarelto | Rivaroxaban | 22 | suppressed |
| Fenofibrate | Fenofibrate | 21 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 20 | suppressed |
| Kerendia | Finerenone | 20 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 20 | suppressed |
| Alprazolam | Alprazolam | 19 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 19 | 14 |
| Linzess | Linaclotide | 19 | suppressed |
| Procto-Med Hc | Hydrocortisone | 19 | suppressed |
| Valsartan | Valsartan | 19 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 18 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 18 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 18 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 17 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 17 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 16 | suppressed |
| Ezetimibe | Ezetimibe | 16 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 16 | suppressed |
| Telmisartan | Telmisartan | 16 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Cyclosporine | Cyclosporine | 15 | suppressed |
| Furosemide | Furosemide | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 15 | 11 |
| Felodipine Er | Felodipine | 14 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 13 | suppressed |
| Brilinta | Ticagrelor | 12 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 12 | 12 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 12 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 11 | suppressed |
| Prednisone | Prednisone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $679.51 · 25 records | Lilly USA, LLC | ACCRUFER, BREZTRI, CREON, FARXIGA, JARDIANCE, Kerendia, LINZESS, MOUNJARO, OTEZLA, REPATHA, ZENPEP, ZEPBOUND, ZORYVE | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error